These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25641676)

  • 1. Vaccination approach to anti-angiogenic treatment of cancer.
    Wentink MQ; Huijbers EJ; de Gruijl TD; Verheul HM; Olsson AK; Griffioen AW
    Biochim Biophys Acta; 2015 Apr; 1855(2):155-71. PubMed ID: 25641676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.
    Kong DH; Kim MR; Jang JH; Na HJ; Lee S
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
    Hegde PS; Wallin JJ; Mancao C
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunotherapy of targeting angiogenesis.
    Hou J; Tian L; Wei Y
    Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
    Mitchell DC; Bryan BA
    J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutraceuticals and their role in tumor angiogenesis.
    Rampino A; Annese T; Margari A; Tamma R; Ribatti D
    Exp Cell Res; 2021 Nov; 408(2):112859. PubMed ID: 34637764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.
    Yetkin-Arik B; Kastelein AW; Klaassen I; Jansen CHJR; Latul YP; Vittori M; Biri A; Kahraman K; Griffioen AW; Amant F; Lok CAR; Schlingemann RO; van Noorden CJF
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188446. PubMed ID: 33058997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance to anti-angiogenic therapy: a clinical and scientific current issue].
    Gu Y; Lu H; Boisson-Vidal C; Li H; Bousquet G; Janin A; Di Benedetto M
    Med Sci (Paris); 2016 Apr; 32(4):370-7. PubMed ID: 27137694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.
    Khan KA; Kerbel RS
    Nat Rev Clin Oncol; 2018 May; 15(5):310-324. PubMed ID: 29434333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor vasculature: the Achilles' heel of cancer?
    Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP
    Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
    Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
    Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
    Gacche RN; Meshram RJ
    Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis inhibitors in cancer therapy.
    Dredge K; Dalgleish AG; Marriott JB
    Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is VEGF a predictive biomarker to anti-angiogenic therapy?
    Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
    Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.
    Li D; Finley SD
    Integr Biol (Camb); 2018 Apr; 10(4):253-269. PubMed ID: 29623971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.